# Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

> **NCT04084769** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 570 (actual)

## Conditions studied

- Meningococcal Immunisation (Healthy Volunteers)

## Interventions

- **BIOLOGICAL:** Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine
- **BIOLOGICAL:** Meningococcal Group B vaccine (Trumenba®)
- **BIOLOGICAL:** Meningococcal group B vaccine (Bexsero®)

## Key facts

- **NCT ID:** NCT04084769
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-03
- **Primary completion:** 2020-09-14
- **Final completion:** 2020-09-14
- **Target enrollment:** 570 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04084769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04084769, "Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04084769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*